|
gptkbp:instanceOf
|
gptkb:drug
beta blocker
|
|
gptkbp:approvalYear
|
1981
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:C08CA05
|
|
gptkbp:bioavailability
|
45-68%
|
|
gptkbp:brand
|
gptkb:Nifediac
gptkb:Procardia
gptkb:Adalat
|
|
gptkbp:CASNumber
|
21829-25-4
|
|
gptkbp:contraindication
|
severe aortic stenosis
unstable angina
cardiogenic shock
|
|
gptkbp:discoveredBy
|
gptkb:Bayer
|
|
gptkbp:drugClass
|
dihydropyridine
|
|
gptkbp:eliminationHalfLife
|
2-5 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
C17H18N2O6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
nifedipine
|
|
gptkbp:interactsWith
|
gptkb:milk
gptkb:phenytoin
gptkb:rifampin
beta blockers
cimetidine
|
|
gptkbp:introducedIn
|
1970s
|
|
gptkbp:KEGGID
|
D00409
|
|
gptkbp:legalStatus
|
prescription only
off-patent
|
|
gptkbp:mechanismOfAction
|
blocks L-type calcium channels
|
|
gptkbp:MedlinePlusID
|
a684028
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
C (US)
B3 (Australia)
|
|
gptkbp:proteinBinding
|
92-98%
|
|
gptkbp:PubChem_CID
|
4485
CHEMBL645
DB01115
|
|
gptkbp:routeOfAdministration
|
oral
sublingual
|
|
gptkbp:sideEffect
|
edema
dizziness
headache
palpitations
flushing
|
|
gptkbp:synonym
|
1,4-dihydropyridine-3,5-dicarboxylic acid, 2,6-dimethyl-4-(2-nitrophenyl)-, dimethyl ester
|
|
gptkbp:UNII
|
9XPW0F3T5E
|
|
gptkbp:usedFor
|
gptkb:Raynaud's_phenomenon
hypertension
angina
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
true
|
|
gptkbp:bfsParent
|
gptkb:CYP3A4
|
|
gptkbp:bfsLayer
|
5
|